Kezar Life Sciences
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Kezar Life Sciences sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Kezar Life Sciences: 6 sponsored US clinical trials, none currently recruiting.
Kezar Life Sciences sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lupus Nephritis, with 1 trials.
Upper-quartile sponsor footprint
Kezar Life Sciences sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
NCT05781750
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
NCT05569759
KZR-261 in Subjects With Advanced Solid Malignancies
NCT05047536
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
NCT04628936
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
NCT04033926
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
NCT03393013
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
Therapeutic Areas
How the Kezar Life Sciences early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 4 completed (67%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Lupus Nephritis (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Kezar Life Sciences: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Kezar Life Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Kezar Life Sciences page
6 registered trials is a research-attention snapshot, not an endorsement of Kezar Life Sciences or any single study.
- None of Kezar Life Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lupus Nephritis is the condition Kezar Life Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lupus Nephritis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Kezar Life Sciences pipeline card: 6 registered trials from official public datasets.Report a data error.